Arjun Agarwal Sells Shares of Oruka Therapeutics
The Senior VP of Finance sold 9,459 shares for over $659,000.
Key Points
- Arjun Agarwal, Senior VP of Finance at Oruka Therapeutics, sold 9,459 shares on June 12, 2026, totaling $659,501.34.
- Oruka Therapeutics' stock traded at $69.89, with a market cap of $4.22 billion and a 52-week range of $10.77 to $91.00.
- Analysts maintain strong buy ratings, with a consensus target price of $142.17 across 12 opinions.
Arjun Agarwal, the Senior Vice President of Finance at Oruka Therapeutics, Inc., sold 9,459 shares of the company on June 12, 2026. The transaction, which was planned, amounted to $659,501.34 at an average price of $69.7221 per share. This sale is part of a broader pattern of insider transactions at the company.
Insider Buying and Selling at Oruka Therapeutics, Inc.
In addition to Agarwal's sale, several other insiders have been active. On June 15, 2026, Joana Goncalves, the Chief Medical Officer, purchased 7,000 shares at $7.32 each, while also selling 3,500 shares at no cost. Laura Lee Sandler, the Chief Operating Officer, sold 600 shares at $69.69 each on the same day. Paul Quinlan, General Counsel, also sold 733 shares at the same price.
Other Institutional Activity in Oruka Therapeutics
Several institutional investors have made recent moves in Oruka Therapeutics. FMR LLC increased its holdings by 170,019 shares, bringing its total to 7,431,403 shares valued at approximately $364.5 million. Paradigm Biocapital Advisors LP made a significant addition of 610,000 shares, now holding 2,320,316 shares worth $113.8 million. However, BlackRock, Inc. slightly reduced its position by 12,328 shares, ending with 3,527,087 shares valued at $173.0 million.
Oruka Therapeutics Stock Snapshot
Shares of Oruka Therapeutics, Inc. (NasdaqGM: ORKA) traded near $69.89. The company has a market cap of about $4.22 billion and a forward P/E ratio indicating it is not currently profitable. The stock's 52-week range spans from $10.77 to $91.00, with a 50-day moving average of $63.701 and a 200-day moving average of $37.60295. Oruka maintains a strong liquidity position with a current ratio of 23.763 and a quick ratio of 23.377.
Analysts Set New Price Targets
Analysts have been active with their ratings on Oruka Therapeutics. On May 14, 2026, BTIG reiterated its buy rating with a price target of $151. UBS and Barclays have also maintained buy ratings with targets of $100 and $160, respectively. The consensus among 12 analysts remains a strong buy, with an average target price of $142.17.
About Oruka Therapeutics
Oruka Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California. Specializing in monoclonal antibody therapeutics, Oruka focuses on treating psoriasis and other inflammatory conditions. The company is led by CEO Dr. Lawrence Otto Klein and employs 68 people. Its key products include ORKA-001 and ORKA-002, both in phase 2 trials targeting psoriasis and related disorders.
Bottom Line
Arjun Agarwal's recent stock sale is part of a series of insider transactions at Oruka Therapeutics, a company focused on innovative treatments for inflammatory diseases. While insider sales can attract attention, they often occur for various reasons unrelated to company performance. Investors should note that 13F filings and insider transactions are backward-looking, reflecting past events and not necessarily current positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.